CN119053601A - 泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途 - Google Patents

泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途 Download PDF

Info

Publication number
CN119053601A
CN119053601A CN202280087378.2A CN202280087378A CN119053601A CN 119053601 A CN119053601 A CN 119053601A CN 202280087378 A CN202280087378 A CN 202280087378A CN 119053601 A CN119053601 A CN 119053601A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
heterocycloalkyl
cycloalkyl
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280087378.2A
Other languages
English (en)
Chinese (zh)
Inventor
吴建平
秦泺恒
刘金鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yingsi Intelligent Technology Intellectual Property Co ltd
Original Assignee
Yingsi Intelligent Technology Intellectual Property Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yingsi Intelligent Technology Intellectual Property Co ltd filed Critical Yingsi Intelligent Technology Intellectual Property Co ltd
Publication of CN119053601A publication Critical patent/CN119053601A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202280087378.2A 2021-11-12 2022-11-11 泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途 Pending CN119053601A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2021130290 2021-11-12
CNPCT/CN2021/130290 2021-11-12
CNPCT/CN2022/123827 2022-10-08
CN2022123827 2022-10-08
PCT/CN2022/131293 WO2023083286A1 (en) 2021-11-12 2022-11-11 Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof

Publications (1)

Publication Number Publication Date
CN119053601A true CN119053601A (zh) 2024-11-29

Family

ID=86335131

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280087378.2A Pending CN119053601A (zh) 2021-11-12 2022-11-11 泛素特异性蛋白酶1(usp1)的小分子抑制剂及其用途

Country Status (19)

Country Link
US (3) US20250026754A1 (enExample)
EP (1) EP4430050A4 (enExample)
JP (1) JP2024543477A (enExample)
KR (1) KR20240117556A (enExample)
CN (1) CN119053601A (enExample)
AR (1) AR127646A1 (enExample)
AU (1) AU2022386486A1 (enExample)
CA (1) CA3235765A1 (enExample)
CL (2) CL2024001397A1 (enExample)
CO (1) CO2024006269A2 (enExample)
CR (1) CR20240191A (enExample)
DO (1) DOP2024000080A (enExample)
GE (1) GEAP202416532A (enExample)
IL (1) IL312642A (enExample)
JO (1) JOP20240096A1 (enExample)
MX (1) MX2024005755A (enExample)
PE (1) PE20241307A1 (enExample)
TW (1) TW202334142A (enExample)
WO (1) WO2023083286A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR127646A1 (es) 2021-11-12 2024-02-14 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
WO2024086790A1 (en) * 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS
WO2025010245A1 (en) 2023-07-06 2025-01-09 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
WO2025101691A1 (en) 2023-11-08 2025-05-15 Exelixis, Inc. Methods for treating cancer using compounds that inhibit pkmyt1
WO2025102016A1 (en) 2023-11-10 2025-05-15 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway
WO2025227060A1 (en) 2024-04-26 2025-10-30 Insilico Medicine Ip Limited Heterocyclic inhibitors of ubiquitin specific protease 1 (usp1) in combination with additional agents for use in the treatment of cancer

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337611A1 (de) 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Benzoylguanidine, ihre Herstellung und ihre Verwendung in Arzneimitteln
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN100340559C (zh) * 1998-12-23 2007-10-03 布里斯托尔-迈尔斯斯奎布药品公司 作为凝血因子xa抑制剂的含氮杂双环
WO2002068419A1 (en) 2001-02-26 2002-09-06 Tanabe Seiyaku Co., Ltd. Pyridopyrimidine or naphthyridine derivative
JP2004083587A (ja) 2002-08-06 2004-03-18 Tanabe Seiyaku Co Ltd 医薬組成物
ITFR20030005U1 (it) 2003-03-17 2003-06-16 C D R Sistema di protezione solare (frangisole f1)
JP2010208945A (ja) 2007-06-01 2010-09-24 Mitsubishi Tanabe Pharma Corp 複素環化合物
JP5063815B2 (ja) 2008-11-25 2012-10-31 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ 抗腫瘍および抗神経変性剤としての二環式ピラゾールおよびイソオキサゾール誘導体
MX2012004846A (es) 2009-10-29 2012-10-05 Genosco Inhibidores de cinasa.
CA2783258A1 (en) 2009-12-23 2011-06-30 Elan Pharmaceuticals, Inc. Pteridinones as inhibitors of polo-like kinase
US20130178475A1 (en) 2010-03-17 2013-07-11 Ironwood Pharmaceuticals, Inc. sGC STIMULATORS
US9242981B2 (en) * 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2013037415A1 (en) 2011-09-16 2013-03-21 Sanofi Substituted 4,5,6,7-tetrahydro-1h-pyrazolo[4,3-c]pyridines, their use as medicament, and pharmaceutical preparations comprising them
EP2938610A2 (en) 2012-12-28 2015-11-04 The U.S.A. as represented by the Secretary, Department of Health and Human Services Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN104311555B (zh) 2014-09-19 2016-04-20 广东东阳光药业有限公司 吡唑并哌啶酮类化合物及其组合物及用途
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
EP3377493B1 (en) 2015-11-20 2020-04-08 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
JP7114076B2 (ja) 2015-12-22 2022-08-08 シャイ・セラピューティクス・エルエルシー がん及び炎症性疾患の処置のための化合物
MA45146A (fr) 2016-05-24 2021-03-24 Constellation Pharmaceuticals Inc Dérivés de pyrazolopyridine pour le traitement du cancer
CA3066939A1 (en) 2017-06-21 2018-12-27 SHY Therapeutics LLC Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2019089216A1 (en) 2017-11-01 2019-05-09 Dana-Farber Cancer Institute, Inc. Methods of treating cancers
AU2019405925B2 (en) * 2018-12-20 2025-07-03 KSQ Therapeutics, Inc. Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (USP1) inhibitors
US20220073525A1 (en) * 2018-12-28 2022-03-10 Forma Therapeutics, Inc. Compositions for inhibiting ubiquitin specific protease 1
US20230277533A1 (en) * 2020-02-14 2023-09-07 KSQ Therapeutics, Inc. Therapeutic combinations comprising ubiquitin-specific-processing protease 1 (usp1) inhibitors and poly (adp-ribose) polymerase (parp) inhibitors
US20230219965A1 (en) 2020-06-02 2023-07-13 KSQ Therapeutics, Inc. Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors
AU2021371305A1 (en) 2020-10-30 2023-06-15 KSQ Therapeutics, Inc. Solid state forms of substituted pyrazolopyrimidines and uses thereof
TW202246255A (zh) 2021-02-12 2022-12-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法
EP4291559A1 (en) 2021-02-15 2023-12-20 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
JP2024511996A (ja) 2021-03-17 2024-03-18 タンゴ セラピューティクス， インコーポレイテッド 抗がん剤としてのプリン誘導体
WO2022199652A1 (en) 2021-03-24 2022-09-29 Impact Therapeutics (Shanghai) , Inc Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof
IL307157A (en) 2021-04-07 2023-11-01 Forma Therapeutics Inc Ubiquitin-specific protease 1 (USP1) inhibition
TW202304933A (zh) 2021-04-09 2023-02-01 大陸商海南耀臻生物醫藥科技有限公司 泛素特異性蛋白酶１（ｕｓｐ１）抑制劑、藥物組合物及其治療哺乳動物由ｕｓｐ１介導的疾病的方法
CN119173515A (zh) 2021-11-12 2024-12-20 英矽智能科技知识产权有限公司 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途
PE20241234A1 (es) 2021-11-12 2024-06-19 Insilico Medicine Ip Ltd Inhibidores de molecula pequena de proteasa especifica de ubiquitina 1 (usp1) y usos de los mismos
AR127646A1 (es) 2021-11-12 2024-02-14 Insilico Medicine Ip Ltd Inhibidores de molécula pequeña de proteasa 1 específica de ubiquitina (usp1) y usos de los mismos
WO2024086790A1 (en) 2022-10-21 2024-04-25 Exelixis, Inc. 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS

Also Published As

Publication number Publication date
US12570634B2 (en) 2026-03-10
US20230183210A1 (en) 2023-06-15
JP2024543477A (ja) 2024-11-21
CR20240191A (es) 2024-09-13
TW202334142A (zh) 2023-09-01
AU2022386486A1 (en) 2024-05-09
CO2024006269A2 (es) 2024-05-30
DOP2024000080A (es) 2024-11-29
GEAP202416532A (en) 2024-08-12
US20240190839A1 (en) 2024-06-13
WO2023083286A1 (en) 2023-05-19
CL2025001068A1 (es) 2025-07-11
IL312642A (en) 2024-07-01
JOP20240096A1 (ar) 2024-04-24
US11739077B2 (en) 2023-08-29
AR127646A1 (es) 2024-02-14
US20250026754A1 (en) 2025-01-23
CL2024001397A1 (es) 2024-10-25
EP4430050A4 (en) 2025-09-24
KR20240117556A (ko) 2024-08-01
CA3235765A1 (en) 2023-05-19
EP4430050A1 (en) 2024-09-18
PE20241307A1 (es) 2024-06-24
MX2024005755A (es) 2024-09-06

Similar Documents

Publication Publication Date Title
CN119173515A (zh) 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途
CN119173512A (zh) 泛素特异性蛋白酶1 (usp1)的小分子抑制剂和其用途
US20260103463A1 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
WO2023114733A1 (en) Kras modulators and uses thereof
US11739077B2 (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof
WO2025049619A1 (en) Kras modulators and uses thereof
WO2025049402A1 (en) Kras modulators and uses thereof
KR101921764B1 (ko) 피라졸로-퀴놀린
US12583838B2 (en) Analogs for the treatment of disease
WO2024109942A1 (zh) Pkmyt1抑制剂、制备方法、药物组合物及其用途
CN111655693B (zh) 抑制瞬时型感受器电位a1离子通道
WO2020029908A1 (zh) 螺桥环化合物、其药物组合物及其用途
CN120322431A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
WO2024153147A1 (zh) 一种氮杂环烷烃化合物、药物组合物及其用途
WO2023177356A2 (en) Compounds and method for pkmyt1 inhibition
EA050901B1 (ru) Низкомолекулярные ингибиторы убиквитин-специфической протеазы 1 (usp1) и их применение
OA21707A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
OA21706A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.
CA3235762A1 (en) Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof
OA21708A (en) Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination